The occurrence of cardiovascular side effects is sometimes associated with the utilization of P-adrenoceptor agonists. The most important causes of these undesirable pharmacologic actions are as follows: (1) Furthermore, hypoxemia and hypokalemia may also contribute to trigger the cardiac side effects of P-adrenoceptor agonists.
T nhaled P-adrenoceptor agonists are the most ef-¦*¦ fective bronchodilators currently available. How¬ ever, stimulation of P-adrenergic receptors (P-AR) sometimes may also induce cardiovascular side ef¬ fects,1"3 such as tachycardia, arrhythmias, prolonga¬ tion of QT interval, and T-wave changes.
These effects, which are quite rare with the use of inhaled P2-selective drugs, depend mainly on reflex release of catecholamines, secondaiy to peripheral vasodilation, and on direct activation of cardiac P-AR.
The latter belong mostly to the Prsubtype, but some P2-receptors coexist with the more numerous psub¬ types in atria and left ventricle. 4 Furthermore, hypoxemia and hypokalemia may also contribute to trigger the cardiac side effects of P-adrenoceptor agonists. 79.50± 10.06, respectively) (Fig 1), or serum levels of sodium, potassium, and magne¬ sium (data not shown). Furthermore, no cardiovas¬ cular symptom was reported by any of the subjects enrolled in the study.
Discussion
The results of our short-term trial have shown that inhaled salmeterol, at both daily doses of 100 Several factors may account for the lack of cardio- 
